2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxyphenoxy]acetic acid | 875802-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxyphenoxy]acetic acid
• CAS: 875802-23-6
• 化学式: C₁₇H₁₇N₃O₆
• 分子量: 359.338
• InChiKey: ZYNXTSGMBMELSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxyphenoxy]acetic acid 、 苯佐卡因 在 polymer-bound morpholine 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以44%的产率得到ethyl 4-[[2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxyphenoxy]acetyl]amino]benzoate
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A_2B Adenosine Receptor

  摘要：

  Over two hundred 1-, 3-, 8-, and 9-substituted-9-deazaxanthines were prepared and evaluated for their binding affinity at the recombinant human adenosine receptors, in particular at the hA(2B) and hA(2A) subtypes. Several ligands endowed with sub-micromolar to low nanomolar binding affinity at hA(2B) receptors, good selectivity over hA(2A) and hA(3), but a relatively poor selectivity over hA(1) were obtained. Good antagonistic potencies and efficacies, with pA(2) values close to the corresponding pK(i)s, were observed in functional assays in vitro performed on a selected series of compounds. 1,3-Dimethyl-8-phenoxy-(N-p-halogenophenyl)-acetamido-9-deazaxanthine derivatives appeared as the most interesting leads, some of them showing outstanding hA(2B) affinities, high selectivity over hA(2A) and hA(3), but low selectivity over hA(1). Structure-affinity relationships suggested that the binding potency at the hA(2B) receptor was mainly modulated by the steric (lipophilic) properties of the substituents at positions 1 and 3 and by the electronic and lipophilic characteristics of the substituents at position 8. A comparison among affinity and selectivity profiles of 9-deazaxanthines with the corresponding xanthines suggested some possible differences in their binding mode.

  DOI：

  10.1021/jm0506221
• 作为产物：
  描述：

  (4-甲酰基-2-甲氧基苯氧基)乙酸 在 哌啶 、 甲酸 、 sodium dithionite 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxyphenoxy]acetic acid
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A_2B Adenosine Receptor

  摘要：

  Over two hundred 1-, 3-, 8-, and 9-substituted-9-deazaxanthines were prepared and evaluated for their binding affinity at the recombinant human adenosine receptors, in particular at the hA(2B) and hA(2A) subtypes. Several ligands endowed with sub-micromolar to low nanomolar binding affinity at hA(2B) receptors, good selectivity over hA(2A) and hA(3), but a relatively poor selectivity over hA(1) were obtained. Good antagonistic potencies and efficacies, with pA(2) values close to the corresponding pK(i)s, were observed in functional assays in vitro performed on a selected series of compounds. 1,3-Dimethyl-8-phenoxy-(N-p-halogenophenyl)-acetamido-9-deazaxanthine derivatives appeared as the most interesting leads, some of them showing outstanding hA(2B) affinities, high selectivity over hA(2A) and hA(3), but low selectivity over hA(1). Structure-affinity relationships suggested that the binding potency at the hA(2B) receptor was mainly modulated by the steric (lipophilic) properties of the substituents at positions 1 and 3 and by the electronic and lipophilic characteristics of the substituents at position 8. A comparison among affinity and selectivity profiles of 9-deazaxanthines with the corresponding xanthines suggested some possible differences in their binding mode.

  DOI：

  10.1021/jm0506221

文献信息

• 6-Phenyldihydropyrrolopyrimidinedione derivatives
  申请人：Vidal Juan Bernat

  公开号：US20050070558A1

  公开（公告）日：2005-03-31

  6-phenylpyrrolopyrimidinedione derivatives of the formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are organic residues, L 1 is a spacer group and R 6 is C(O) NR 10 R 11 , —S(O) 2 NR 10 R 11 , ? —ON═CR 12 R 13 , or a heterocyclyl, aryl? or heteroaryl group, where R 10 , R 11 , R 12 and R 13 are organic residues, have therapeutic potential as A2 adenosine receptor inhibitors.

  式(I)的6-苯基吡咯嘧啶二酮衍生物及其药学上可接受的盐，其中R1、R2、R3、R4和R5均为有机残基，L1为间隔基，R6为C（O）NR10R11、—S（O）2NR10R11、？—ON═CR12R13或杂环基、芳基或杂芳基，其中R10、R11、R12和R13为有机残基，具有作为A2腺苷受体抑制剂的治疗潜力。
• 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor
  作者：Angela Stefanachi、Jose Manuel Brea、Maria Isabel Cadavid、Nuria B. Centeno、Cristina Esteve、Maria Isabel Loza、Ana Martinez、Rosa Nieto、Enrique Raviña、Ferran Sanz

  DOI：10.1016/j.bmc.2008.01.002

  日期：2008.3.15

  A large series of piperazin-, piperidin- and tetrahydroisoquinolinamides of 4-(1,3-dialkyl-9-deazaxanthin-8-yl)phenoxyacetic acid were prepared through conventional or multiple parallel syntheses and evaluated for their binding affinity at the recombinant human adenosine receptors, chiefly at the hA(2B) and hA(2A) receptor subtypes. Several ligands endowed with high binding affinity at hA(2B) receptors, excellent selectivity over hA(2A) and hA(3) and a significant, but lower, selectivity over hA(1) were identified. Among them, piperazinamide derivatives 23 and 52, and piperidinamide derivative 69 proved highly potent at hA2B (K-i = 11, 2 and 5.5 nM, respectively) and selective towards hA(2A) (hA(2A)/hA(2B) SI = 912, 159 and 630, respectively), hA(3) (hA(3)/hA(2B) SI = > 100, 3090 and >180, respectively) and hA(1) (hA(1)/hA(2B) SI = > 100, 44 and 120, respectively), SI being the selectivity index. A number of selected ligands tested in functional assays in vitro showed very interesting antagonist activities and efficacies at both A(2A) and A(2B) receptor subtypes, with pA(2) values close to the corresponding pK(i)s. Structure-affinity and structure-selectivity relationships suggested that the binding potency at the hA(2B) receptor may be increased by lipophilic substituents at the N4-position of piperazinamides and that an ortho-methoxy substituent at the 8-phenyl ring and alkyl groups at NI larger than the ones at N3, in the 9-deazaxanthine ring, may strongly enhance the hA(2A)/hA(2B) SI. (C) 2008 Elsevier Ltd. All rights reserved.
• RUBBER COMPOUNDING FORMULATION AND METHOD
  申请人：UNIROYAL CHEMICAL COMPANY, Inc.

  公开号：EP0742810A1

  公开（公告）日：1996-11-20
• [EN] RUBBER COMPOUNDING FORMULATION AND METHOD<br/>[FR] FORMULATION POUR MELANGE DE CAOUTCHOUC ET PROCEDE ASSOCIE
  申请人：UNIROYAL CHEMICAL COMPANY, INC.

  公开号：WO1995021214A1

  公开（公告）日：1995-08-10

  (EN) This disclosure is directed to an antioxidant compound which reduces the rate at which insoluble sulfur converts to a migratable form of sulfur in an unvulcanized compound.(FR) Cette invention concerne un composé antioxydant qui réduit la vitesse à laquelle le soufre insoluble se transforme en une forme de soufre apte à migrer, dans un composé non vulcanisé.
• [EN] 1,2-DIHYDROQUINOLINE DERIVATIVES AND METHOD FOR USING THE SAME TO TREAT HIV INFECTION<br/>[FR] DERIVES DE LA 1,2-DIHYDROQUINOLINE ET LEUR METHODE D'UTILISATION POUR TRAITER LES INFECTIONS PAR LE VIH
  申请人：WYETH CORP

  公开号：WO2005090309A1

  公开（公告）日：2005-09-29

  The present invention is directed to compound of formula (A): wherein R1 is selected from (a) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl, or (b) CN and -C(NR10R11)=N-R12 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl, R3-R12 are as described within the specification, and A is O, NR9 or S, or a prodrug, a pharmaceutically acceptable salt or a pharmaceutically active metabolite thereof, provided that R1 is not alkyl when R2 is pyridine, provided that at least one of R3-R8 is not H or F when A is O, R1 is (b) and R2 is a phenyl ring, a phenyl ring substituted at the para position with halo, -CN, -OCH3 or -CO2CH3, a quinoline or an ethylene substituted with a phenyl ring or a 3,4-methylenedioxyphenyl moiety, provided that R4 is not methyl when R3 and R5-R8 are H, A is O, R1 is (b) and R2 is 4-chlorophenyl, and provided that R6 is not C1 when R3-R5 and R7-R8 are H, R1 is CN and R2 is phenyl. This invention is also directed to methods of using the same for treating HIV infections or AIDS, or preventing replication.